<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01256801</url>
  </required_header>
  <id_info>
    <org_study_id>GMPE</org_study_id>
    <nct_id>NCT01256801</nct_id>
  </id_info>
  <brief_title>Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion</brief_title>
  <acronym>GMPE</acronym>
  <official_title>Gene Expression Profiling of Breast Cancer Cells in Pleural Effusion Prodict the Response of Malignant Pleural Effusion to Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to develop a gene expression profile for the prediction of&#xD;
      immunotherapy response of patients with metastatic breast cancer presenting malignant pleural&#xD;
      effusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. The patiets with malignant pleural effusion are randomizned to be treated with&#xD;
           cytokins(inteleukin 2) or dendritic cells(DC) plus cytokine induced killer cells(CIK)&#xD;
           locally.&#xD;
&#xD;
        2. Malignant pleural effusion from metastatic breast cancer patient is obtained through&#xD;
           thoracentesis and is centrifugalized to enrich cancer cells before the therapy.&#xD;
&#xD;
        3. The enriched cancer cells are flash frozen and stored at -80℃ until processing.&#xD;
&#xD;
        4. The gene expression in pleural effusion is detected by microarray to screen gene markers&#xD;
           that are differently expressed between groups .&#xD;
&#xD;
        5. Statistical analysis is performed using unsupervised hierarchical cluster.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>immunotherapy response</measure>
    <time_frame>1 month</time_frame>
    <description>Response of malignant pleural effusion to immunotherapy is evaluated with WHO guidelines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>immunological status</measure>
    <time_frame>1 month</time_frame>
    <description>compare the immunological status of pleural effusion before and after the therapy</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">36</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Gene Expression Profiling</condition>
  <condition>Immunotherapy</condition>
  <arm_group>
    <arm_group_label>cytokine</arm_group_label>
    <description>The patients are randomized to receive the cytokine infusion in the pleural cavity</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cytokine</intervention_name>
    <description>interleukin 2 2 million unit every week</description>
    <arm_group_label>cytokine</arm_group_label>
    <other_name>interleukin 2 2 million unit every week</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The cancer cells are taken from the malignant pleural effusion of breast cancer patiets.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The breast cancer patiets present with pleural effusion and can receive chemotherapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients should be histologically confirmed with metastatic breast cancer and&#xD;
             malignant pleural effusion&#xD;
&#xD;
          -  an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;&#xD;
&#xD;
          -  At least one measurable lesion;&#xD;
&#xD;
          -  Normal cardiac, hepatic, renal and bone marrow functions;&#xD;
&#xD;
          -  Life expectancy ≥3 months;&#xD;
&#xD;
          -  Discontinuity of previous chemotherapy for a minimum of 4 weeks.&#xD;
&#xD;
          -  Not receive chemotherapy in pleural cavity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous history of other malignancies;&#xD;
&#xD;
          -  previous surgery history on the needle biopsy organ;&#xD;
&#xD;
          -  Serious or uncontrolled concurrent medical illness.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JUN REN, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>December 1, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Jun Ren</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Metastatic Breast Neoplasms</keyword>
  <keyword>Gene Expression Profiling</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

